RIGL Rigel Pharmaceuticals, Inc.

+0  (10%)
Previous Close 2.77
Open 2.78
Price To book 5.00
Market Cap 372.97M
Shares 122,285,000
Volume 1,847,786
Short Ratio 2.51
Av. Daily Volume 1,137,730

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 preliminary data released January 5, 2017. Enrollment of second cohort to be completed in 2017 with data due in 2018.
IgA nephropathy
Phase 2 trial did not meet endpoints
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. NDA filing due 1Q 2017.
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data from first of two stages due in 2017.
Autoimmune hemolytic anemia (AIHA)

Latest News

  1. After Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere?
  2. Will Rigel Pharmaceuticals (RIGL) Continue to Surge Higher?
  3. 3 Beaten-Up Biotech Stocks: Are They Bargains?
  4. 3 Stocks That Are Ridiculously Cheap Right Now
  5. 5 Cheap Breakout Stocks for Superb Returns
  7. Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
  8. Edited Transcript of RIGL earnings conference call or presentation 7-Mar-17 10:00pm GMT
  9. Rigel reports 4Q loss
  10. Rigel reports 4Q loss
  11. RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  12. Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update
  13. Q4 2016 Rigel Pharmaceuticals Inc Earnings Release - After Market Close
  14. Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results
  15. 3 Cheap Healthcare Stocks You Can Buy Right Now
  16. (2/23) Today's Top 10 Long/Short Estimize Signal Scores
  17. RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
  18. Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
  19. RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  20. Rigel Announces Pricing Of Public Offering Of Common Stock